ABSTRACT
INTRODUCTION

Patient materials.
Serum and plasma samples were purchased from Boca Biolistics (Pompano Beach, USA). 
182
The mean fluorescent intensity (MFI) for each well with a positive signal were generated using 
195
we could perform ZIKV amplification and detect ZIKV-specific Abs using the on-chip nanowells.
196
As a proof-of-concept, we utilized monoclonal anti-ZIKV clone ZV-2, which has been shown to 
203
As presented in Figure 1A , monoclonal anti-ZIKV clone ZV-2 was able to bind to ZIKV E protein 204 as anticipated. Additionally, the microengraving process was able to detect the IgG and IgA, but 
229
Combining microengraving and real-time PCR for clinical samples.
230
We selected eight patients that originated from the Dominican Republic in the post- Table 1 . ZIKV-infected patients were initially exanimated for developing a humoral 233 response against ZIKV and presented high serological titer (IgG 8.54 -20.4) using ELISA 234 (Table 2) . Further testing was performed to detect the presence of neutralizing antibody titer 235 against ZIKV using PRNT. All patients had a neutralizing antibody titer, and six patients (45%) were negative for ZIKV using conventional real-time PCR. To detect and characterize antibody 238 profiles in patients, we analyzed samples using the microengraving serological assay. As 
242
IgG, IgA, and ZIKV E protein and negative for IgM (Figure 2, Table 2 ). Since the samples were 243 negative for ZIKV using conventional real-time PCR, we spiked the serum samples with ZIKV at 244 different dilutions (1, 10, 100, and 1000 copies per nanowells predicted by Poisson distribution).
245
The spiked samples were subjected to real-time PCR using the nanowells, and similar to Figure   246 2, the spiked samples were positive for ZIKV with a positive correlation (data not shown). These 247 results demonstrate the ability to simultaneously detect ZIKV-specific antibodies and RNA using 248 the nanowell chip assay. 
